Medtech startup Quibim has garnered $50 million through a Series A funding round. The company’s groundbreaking work involves the creation of AI models designed to revolutionize medical imaging. Areas including oncology, neurology, immunology, and metabolic diseases are set to benefit from Quibim’s innovative technologies.
Through its groundbreaking AI applications, the firm aims to improve the accuracy of diagnoses and disease detection derived from a range of visual data. Types of imagery include X-rays, MRIs, and CT scans. QP-Prostate, Quibim’s flagship product, is developed to enhance the detection rate of prostate cancer. Future product offerings, still in development, are targeting the brain, breast, lung, and liver.
The Spanish-originated startup has funding totaling around $70M till date and with the latest financial backing, is poised to strengthen its foothold in the U.S market. Quibim recently received FDA 510(k) clearance to promote its QP-Prostate solution. Further, the company has confirmed the hiring of its inaugural chief medical officer based in the U.S.
In terms of a global presence, the firm claims connections to around 170 installations worldwide, including collaborations with Stanford University and Mass General Brigham, a leading healthcare system affiliated with Harvard. Notably, Quibim’s AI models are slated for integration into Philips’ scanners.
Speaking on the latest fundraising success, Ángel Alberich-Bayarri, CEO and co-founder of Quibim, shared the company’s vision of leveraging imaging to pioneer precision health. He marked the U.S expansion as a pivotal point in efforts to revolutionize diagnostics and enhance patient outcomes.
Original source: Read the full article on TechCrunch
